Theresa Ann Case Hollander, CRNP Clinical Nurse Specialist - Adult Health Medicare: Medicare Enrolled Practice Location: 1200 Old York Road, 5 Toll, Abington, PA 19001 Phone: 215-481-4200 Fax: 215-881-9587 |
Mrs. Jamie Kay Tamburino, MSN, CRNP,CWOCN Clinical Nurse Specialist - Adult Health Medicare: Not Enrolled in Medicare Practice Location: 1200 Old York Rd, Abington, PA 19001 Phone: 215-481-7978 |
Denise Rageis, RN, PMHCNS-BC Clinical Nurse Specialist - Psych/Mental Health, Adult Medicare: Accepting Medicare Assignments Practice Location: 1021 Old York Rd Ste 301, Abington, PA 19001 Phone: 215-395-8266 Fax: 215-754-0989 |
Carol Gerhard-lynn, CRNP Clinical Nurse Specialist Medicare: Medicare Enrolled Practice Location: 1235 Old York Rd, Suite 210, Abington, PA 19001 Phone: 215-517-1100 Fax: 215-517-1129 |
News Archive
There is strong evidence showing that individuals who experienced chronic pain during childhood have chronic pain as adults, but few studies have evaluated the characteristics of pain that persists from childhood through adult years. Researchers from the University of Michigan found that one in six adult pain patients had pain as children or adolescents, and their pain was widespread and neuropathic with psychological comorbidities and decreased function.
Millennium Research Group (MRG), the global authority on medical technology market intelligence, finds that vertebroplasty and vertebral augmentation (which includes kyphoplasty) procedures have dropped 10% following the August 2009 publication of two studies in the New England Journal of Medicine (NEJM).
Cephalon, Inc. confirmed today that it received an unsolicited proposal from Valeant Pharmaceuticals International, Inc., on March 18th to acquire the Company for $73 per share and a second unsolicited proposal on March 25th to either acquire the Company for $73 per share or to purchase Cephalon's non-oncology related assets for $2.8 billion. On March 29th, Valeant announced an unsolicited proposal to acquire all of the outstanding shares in the Company for $73 per share.
Pearl Therapeutics Inc. announced plans to make 11 presentations at upcoming medical meetings to report clinical and product development information pertaining to PT003 (GFF MDI), a proprietary, fixed-dose combination of glycopyrrolate (GP), a long-acting muscarinic antagonist (LAMA) and formoterol fumarate (FF), a long-acting beta-2 agonist.
A new study examining the overall and gender-related effects of laparoscopic gastric banding surgery (LGBS) on insulin resistance, body composition, and metabolic risk markers six months post-surgery has found significant improvements in insulin resistance.
› Verified 8 days ago